Ann: CHM CDH17 Phase 1/2 clinical trial approved for initiation, page-17

I attended today's briefing in Sydney:

• Well attended and generally upbeat;
• Rebecca was articulate and hit the right notes with her presentation;
• Wouldnt be surprised if she steps into the CEO role at some future date;
• All 4 clinical trials are progressing well;
• Interim data read outs are expected in Q3 and Q4. (Earlier than expected!);
• She confirmed my view that CDH17 is the jewel in the crown - biggest addressable market and leading tech in-licensed from the pioneers of CART therapies;
• FDA interactions have been positive - Orphan Drug Status will be a no brainer for some of the therapies. Similarly, Fast Track Designation definitely on the cards;
• Paul Hopper did not attend as he was OS on other business (disappointing but I knew he was not in AU);